| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
Endogenous Metabolite
|
|---|---|
| ln Vitro |
1. Analytical Method Development:
- A reversed-phase HPLC method was established using a C18 column (250×4.6 mm, 5 μm) with UV detection at 254 nm. The mobile phase was 0.1 M potassium dihydrogen phosphate (pH 3.5)-methanol (90:10, v/v), enabling simultaneous quantification of S-Adenosyl-L-methionine iodide (SAMe iodide) and S-adenosyl-L-homocysteine (SAH) in mouse liver. Detection limits were 0.15 μmol/g (SAMe iodide) and 0.20 μmol/g (SAH). Recovery rates were 92.1±3.8% (SAMe iodide) and 90.5±4.2% (SAH), with intra- and inter-day precision RSD <5% [1]
2. Effect of Methionine Supplementation: - Oral administration of methionine (200 mg/kg) to mice significantly increased hepatic SAMe iodide concentrations from baseline (3.2±0.3 μmol/g) to 5.8±0.4 μmol/g within 2 hours, without altering SAH levels. The SAMe/SAH ratio remained unchanged (1.8±0.2 vs. 1.7±0.1), indicating methionine primarily enhances SAMe iodide synthesis rather than inhibiting SAH hydrolysis [1] According to She et al., the process of perchloric acid extraction results in the conversion of SAM into S-adenosyl-L-homocysteine by donating the methyl group. SAM and (SAH) separation[1]. |
| Toxicity/Toxicokinetics |
Effects During Pregnancy and Lactation
◉ Overview of Use During Lactation SAM-e (S-adenosylmethionine) is a naturally occurring methyl radical donor involved in enzymatic transmethylation reactions in humans and animals. SAM-e has no specific lactation-related use, but it has been used to treat postpartum depression, cholestatic jaundice, osteoarthritis, and many other conditions. SAM-e has low oral bioavailability. SAM-e is generally well tolerated in adults. The most common adverse reactions are gastrointestinal reactions, such as nausea. Skin rashes have also been reported. There is currently no clinical information regarding the use of SAM-e during lactation. However, it is not expected that SAM-e taken by breastfeeding mothers will have any adverse effects on breastfed infants, especially if the infant is older than 2 months. Dietary supplements do not require extensive premarket approval from the U.S. Food and Drug Administration (FDA). Manufacturers are responsible for ensuring the safety of their products but are not required to demonstrate the safety and efficacy of dietary supplements before they are marketed. Dietary supplements may contain multiple ingredients, and there is often a difference between the ingredients listed on the label and the actual ingredients or amounts. Manufacturers may commission independent organizations to verify the quality of their products or their ingredients, but this does not guarantee that the product has been certified safe or effective. Given these issues, clinical trial results for one product may not apply to other products. For more detailed information on dietary supplements, please visit other pages on the LactMed website. ◉ Effects on breastfed infants No published information found as of the revision date. ◉ Effects on lactation and breast milk No published information found as of the revision date. |
| References | |
| Additional Infomation |
Physiologic methyl radical donors participate in enzymatic transmethylation reactions and are present in all organisms. They possess anti-inflammatory activity and have been used to treat chronic liver disease. (Excerpt from Merck, 11th edition)
|
| Molecular Formula |
C15H23IN6O5S
|
|---|---|
| Molecular Weight |
526.35
|
| Exact Mass |
526.05
|
| CAS # |
3493-13-8
|
| Related CAS # |
S-Adenosyl-L-methionine tosylate;52248-03-0;S-Adenosyl-L-methionine;29908-03-0
|
| PubChem CID |
10143006
|
| Appearance |
White to off-white solid powder
|
| Hydrogen Bond Donor Count |
5
|
| Hydrogen Bond Acceptor Count |
11
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
28
|
| Complexity |
533
|
| Defined Atom Stereocenter Count |
5
|
| SMILES |
C[S+](CC[C@@H](C(=O)[O-])N)C[C@@H]1[C@H]([C@H]([C@H](N2C=NC3=C(N)N=CN=C32)O1)O)O.I
|
| InChi Key |
XQMWYLXPEGFCFT-XKGORWRGSA-N
|
| InChi Code |
InChI=1S/C15H22N6O5S.HI/c1-27(3-2-7(16)15(24)25)4-8-10(22)11(23)14(26-8)21-6-20-9-12(17)18-5-19-13(9)21;/h5-8,10-11,14,22-23H,2-4,16H2,1H3,(H2-,17,18,19,24,25);1H/t7-,8+,10+,11+,14+,27?;/m0./s1
|
| Chemical Name |
[(3S)-3-amino-3-carboxypropyl]-[[(2S,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl]-methylsulfanium;iodide
|
| Synonyms |
EINECS 222-486-5; S-(5'-Deoxy-5'-adenosyl)methionine iodide; RefChem:884153; 222-486-5; 3493-13-8; AKOS024284735; ST078876; 2-amino-6-[5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]-5-methyl-5-thiahexa noic acid, iodide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.8999 mL | 9.4994 mL | 18.9988 mL | |
| 5 mM | 0.3800 mL | 1.8999 mL | 3.7998 mL | |
| 10 mM | 0.1900 mL | 0.9499 mL | 1.8999 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
